ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
43 announcements with these filters
Neuland Laboratories convened its 42nd AGM for August 4, 2026. Agenda includes adopting financial statements and declaring a ₹34 per share final dividend.
Neuland reported record performance for Q4FY26, driven by high-value CMS commercial projects and favorable exchange rates, achieving an exceptional 40.5% EBITDA margin.
Neuland Laboratories' March 2026 API Product List showcases a robust portfolio across diverse therapeutic segments including anticoagulants, antipsychotics, and peptides.
Neuland Laboratories issued a correction fixing a typographical error in its FY26 press release header. Financial data remains unchanged from the original results disclosure.
Neuland Laboratories appointed Dr. Mauricio Futran as a Non-Executive Director effective May 12, 2026. He brings over 40 years of pharmaceutical manufacturing and strategic development experience.
Neuland Laboratories recommended a final dividend of ₹34 per equity share for 2026. The record date is July 24, with payment expected by August 19.
Neuland Laboratories delivered strong FY26 results with significant revenue and profit scaling, driven by the CMS business and commercial molecules. Strategy focuses on high-margin niches, peptides, and a new R&D center.
Neuland Laboratories reported FY26 total income of ₹2053.1 Crore and EBITDA of ₹603.4 Crore. Annual performance shows strong execution discipline and positive business visibility.
Neuland Laboratories Ltd reported revenue from operations of ₹776.3 Cr (+136.4% YoY) and net profit of ₹212.7 Cr (+665.1% YoY) for Q4 FY26.
Neuland Laboratories reported annual financial results and recommended a ₹34 per share dividend. It also announced a ₹143.4 Crore capacity expansion at its Unit 1 facility.
Neuland Laboratories Limited has scheduled a Board Meeting for May 12, 2026, to consider audited financial results for the year ended March 31, 2026, and a final dividend. The trading window for designated persons is closed from April 1 to May 14, 2026.
Neuland Laboratories Ltd has scheduled a Board Meeting on May 12, 2026, to approve the audited financial results for the quarter and year ended March 31, 2026. The board will also consider recommending a final dividend for FY 2025-26. Consequently, the trading window for company shares remains closed until 48 hours post-declaration.
Neuland Laboratories Ltd submitted an Annual Compliance Certificate for Davuluri Ownership Trust for FY 2025-26. Issued by M/s. B Srinivasa Rao & Co., the certificate confirms compliance with the SEBI Exemption Order dated January 3, 2025. This is a routine regulatory filing for information and record purposes.